Receipt of Cancer Screening Is a Predictor of Life Expectancy

James Goodwin, Kristin Sheffield, Shuang Li, Alai Tan

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Background: Obtaining cancer screening on patients with limited life expectancy has been proposed as a measure for low quality care for primary care physicians (PCPs). However, administrative data may underestimate life expectancy in patients who undergo screening. Objective: To determine the association between receipt of screening mammography or PSA and overall survival. Design: Retrospective cohort study from 1/1/1999 to 12/31/2012. Receipt of screening was assessed for 2001–2002 and survival from 1/1/2003 to 12/31/2012. Life expectancy was estimated as of 1/1/03 using a validated algorithm, and was compared to actual survival for men and women, stratified by receipt of cancer screening. Participants: A 5 % sample of Medicare beneficiaries aged 69–90 years as of 1/1/2003 (n = 906,723). Interventions: Receipt of screening mammography in 2001–2002 for women, or a screening PSA test in 2002 for men. Main Measures: Survival from 1/1/2003 through 12/31/2012. Key Results: Subjects were stratified by life expectancy based on age and comorbidity. Within each stratum, the subjects with prior cancer screening had actual median survivals higher than those who were not screened, with differences ranging from 1.7 to 2.1 years for women and 0.9 to 1.1 years for men. In a Cox model, non-receipt of screening in women had an impact on survival (HR = 1.52; 95 % CI = 1.51, 1.54) similar in magnitude to a diagnosis of complicated diabetes or heart failure, and was comparable to uncomplicated diabetes or liver disease in men (HR = 1.23; 1.22, 1.25). Conclusions: Receipt of cancer screening is a powerful marker of health status that is not captured by comorbidity measures in administrative data. Because life expectancy algorithms using administrative data underestimate the life expectancy of patients who undergo screening, they can overestimate the problem of cancer screening in patients with limited life expectancy.

Original languageEnglish (US)
Pages (from-to)1-7
Number of pages7
JournalJournal of General Internal Medicine
DOIs
StateAccepted/In press - Jun 30 2016

Fingerprint

Life Expectancy
Early Detection of Cancer
Survival
Mammography
Comorbidity
Quality of Health Care
Primary Care Physicians
Medicare
Proportional Hazards Models
Health Status
Liver Diseases
Cohort Studies
Heart Failure
Retrospective Studies

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Receipt of Cancer Screening Is a Predictor of Life Expectancy. / Goodwin, James; Sheffield, Kristin; Li, Shuang; Tan, Alai.

In: Journal of General Internal Medicine, 30.06.2016, p. 1-7.

Research output: Contribution to journalArticle

@article{1d373cc366af4656b9c4a3b766dfae74,
title = "Receipt of Cancer Screening Is a Predictor of Life Expectancy",
abstract = "Background: Obtaining cancer screening on patients with limited life expectancy has been proposed as a measure for low quality care for primary care physicians (PCPs). However, administrative data may underestimate life expectancy in patients who undergo screening. Objective: To determine the association between receipt of screening mammography or PSA and overall survival. Design: Retrospective cohort study from 1/1/1999 to 12/31/2012. Receipt of screening was assessed for 2001–2002 and survival from 1/1/2003 to 12/31/2012. Life expectancy was estimated as of 1/1/03 using a validated algorithm, and was compared to actual survival for men and women, stratified by receipt of cancer screening. Participants: A 5 {\%} sample of Medicare beneficiaries aged 69–90 years as of 1/1/2003 (n = 906,723). Interventions: Receipt of screening mammography in 2001–2002 for women, or a screening PSA test in 2002 for men. Main Measures: Survival from 1/1/2003 through 12/31/2012. Key Results: Subjects were stratified by life expectancy based on age and comorbidity. Within each stratum, the subjects with prior cancer screening had actual median survivals higher than those who were not screened, with differences ranging from 1.7 to 2.1 years for women and 0.9 to 1.1 years for men. In a Cox model, non-receipt of screening in women had an impact on survival (HR = 1.52; 95 {\%} CI = 1.51, 1.54) similar in magnitude to a diagnosis of complicated diabetes or heart failure, and was comparable to uncomplicated diabetes or liver disease in men (HR = 1.23; 1.22, 1.25). Conclusions: Receipt of cancer screening is a powerful marker of health status that is not captured by comorbidity measures in administrative data. Because life expectancy algorithms using administrative data underestimate the life expectancy of patients who undergo screening, they can overestimate the problem of cancer screening in patients with limited life expectancy.",
author = "James Goodwin and Kristin Sheffield and Shuang Li and Alai Tan",
year = "2016",
month = "6",
day = "30",
doi = "10.1007/s11606-016-3787-y",
language = "English (US)",
pages = "1--7",
journal = "Journal of General Internal Medicine",
issn = "0884-8734",
publisher = "Springer New York",

}

TY - JOUR

T1 - Receipt of Cancer Screening Is a Predictor of Life Expectancy

AU - Goodwin, James

AU - Sheffield, Kristin

AU - Li, Shuang

AU - Tan, Alai

PY - 2016/6/30

Y1 - 2016/6/30

N2 - Background: Obtaining cancer screening on patients with limited life expectancy has been proposed as a measure for low quality care for primary care physicians (PCPs). However, administrative data may underestimate life expectancy in patients who undergo screening. Objective: To determine the association between receipt of screening mammography or PSA and overall survival. Design: Retrospective cohort study from 1/1/1999 to 12/31/2012. Receipt of screening was assessed for 2001–2002 and survival from 1/1/2003 to 12/31/2012. Life expectancy was estimated as of 1/1/03 using a validated algorithm, and was compared to actual survival for men and women, stratified by receipt of cancer screening. Participants: A 5 % sample of Medicare beneficiaries aged 69–90 years as of 1/1/2003 (n = 906,723). Interventions: Receipt of screening mammography in 2001–2002 for women, or a screening PSA test in 2002 for men. Main Measures: Survival from 1/1/2003 through 12/31/2012. Key Results: Subjects were stratified by life expectancy based on age and comorbidity. Within each stratum, the subjects with prior cancer screening had actual median survivals higher than those who were not screened, with differences ranging from 1.7 to 2.1 years for women and 0.9 to 1.1 years for men. In a Cox model, non-receipt of screening in women had an impact on survival (HR = 1.52; 95 % CI = 1.51, 1.54) similar in magnitude to a diagnosis of complicated diabetes or heart failure, and was comparable to uncomplicated diabetes or liver disease in men (HR = 1.23; 1.22, 1.25). Conclusions: Receipt of cancer screening is a powerful marker of health status that is not captured by comorbidity measures in administrative data. Because life expectancy algorithms using administrative data underestimate the life expectancy of patients who undergo screening, they can overestimate the problem of cancer screening in patients with limited life expectancy.

AB - Background: Obtaining cancer screening on patients with limited life expectancy has been proposed as a measure for low quality care for primary care physicians (PCPs). However, administrative data may underestimate life expectancy in patients who undergo screening. Objective: To determine the association between receipt of screening mammography or PSA and overall survival. Design: Retrospective cohort study from 1/1/1999 to 12/31/2012. Receipt of screening was assessed for 2001–2002 and survival from 1/1/2003 to 12/31/2012. Life expectancy was estimated as of 1/1/03 using a validated algorithm, and was compared to actual survival for men and women, stratified by receipt of cancer screening. Participants: A 5 % sample of Medicare beneficiaries aged 69–90 years as of 1/1/2003 (n = 906,723). Interventions: Receipt of screening mammography in 2001–2002 for women, or a screening PSA test in 2002 for men. Main Measures: Survival from 1/1/2003 through 12/31/2012. Key Results: Subjects were stratified by life expectancy based on age and comorbidity. Within each stratum, the subjects with prior cancer screening had actual median survivals higher than those who were not screened, with differences ranging from 1.7 to 2.1 years for women and 0.9 to 1.1 years for men. In a Cox model, non-receipt of screening in women had an impact on survival (HR = 1.52; 95 % CI = 1.51, 1.54) similar in magnitude to a diagnosis of complicated diabetes or heart failure, and was comparable to uncomplicated diabetes or liver disease in men (HR = 1.23; 1.22, 1.25). Conclusions: Receipt of cancer screening is a powerful marker of health status that is not captured by comorbidity measures in administrative data. Because life expectancy algorithms using administrative data underestimate the life expectancy of patients who undergo screening, they can overestimate the problem of cancer screening in patients with limited life expectancy.

UR - http://www.scopus.com/inward/record.url?scp=84976469141&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84976469141&partnerID=8YFLogxK

U2 - 10.1007/s11606-016-3787-y

DO - 10.1007/s11606-016-3787-y

M3 - Article

C2 - 27364834

AN - SCOPUS:84976469141

SP - 1

EP - 7

JO - Journal of General Internal Medicine

JF - Journal of General Internal Medicine

SN - 0884-8734

ER -